BML-111 attenuates hemorrhagic shock-induced acute lung injury through inhibiting activation of mitogen-activated protein kinase pathway in rats

J Surg Res. 2013 Aug;183(2):710-9. doi: 10.1016/j.jss.2013.03.007. Epub 2013 Mar 26.

Abstract

Background: Hemorrhagic shock activates cellular stress signals and can lead to systemic inflammatory response, organ injury, and death. Mitogen-activated protein kinase (MAPK) acts as a sensor of tissue injury in models of ischemia-reperfusion injury. Lipoxins are endogenous lipid mediators with potent anti-inflammatory and pro-resolving actions. We hypothesized that BML-111 (a lipoxin A4-receptor agonist) attenuates hemorrhagic shock-induced acute lung injury (ALI) through inhibiting activation of the MAPK pathway.

Methods: We randomized Sprague-Dawley rats into four groups: sham, hemorrhagic shock-resuscitation (HS), HS plus BML-111 (BML-111), and HS plus BML-111 and BOC-2 (BOC-2). Two hours after resuscitation, we collected samples of lung. We obtained bronchoalveolar lavage fluid for neutrophil count. We performed optical microscopy to examine pathologic changes in lungs. Wet/dry ratios, myeloperoxidase expression, interleukin (IL)-1β and IL-6 levels in lung were measured. We evaluated MAPK activation and the DNA binding activity of activator protein-1 in lung.

Results: Treatment with BML-111 reduced the lung damage and wet/dry ratio, neutrophil count in bronchoalveolar lavage fluid, expression of myeloperoxidase, and production of IL-1β and IL-6 in lung. Phosphorylation of MAPK was also decreased by BML-111 in lung. Furthermore, the DNA binding activity of activator protein-1 was blocked by BML-111. An antagonist of the lipoxin A4-receptor, BOC-2, reversed the protective effect of BML-111 on ALI induced by hemorrhagic shock.

Conclusions: This study indicates that BML-111 attenuated hemorrhagic shock-induced ALI via the MAPK/activator protein-1 signaling pathway. Therefore, BML-111 may have therapeutic potential for hemorrhagic shock-induced ALI.

Keywords: Acute lung injury; BML-111; Hemorrhagic shock; Inflammation; MAPK.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / etiology*
  • Acute Lung Injury / metabolism
  • Acute Lung Injury / prevention & control*
  • Animals
  • Disease Models, Animal
  • Heptanoic Acids / pharmacology
  • Heptanoic Acids / therapeutic use*
  • Interleukin-1beta / metabolism
  • Interleukin-6 / metabolism
  • Lung / drug effects
  • Lung / metabolism
  • Lung / pathology
  • Male
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors*
  • Mitogen-Activated Protein Kinase Kinases / drug effects
  • Mitogen-Activated Protein Kinase Kinases / physiology
  • Oligopeptides / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Lipoxin / agonists
  • Receptors, Lipoxin / antagonists & inhibitors
  • Receptors, Lipoxin / drug effects
  • Shock, Hemorrhagic / complications*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*
  • Transcription Factor AP-1 / antagonists & inhibitors
  • Transcription Factor AP-1 / drug effects
  • Transcription Factor AP-1 / physiology

Substances

  • 5(S),6(R)-7-trihydroxyheptanoic acid, methyl ester
  • Heptanoic Acids
  • Interleukin-1beta
  • Interleukin-6
  • Oligopeptides
  • Receptors, Lipoxin
  • Transcription Factor AP-1
  • lipoxin A(4) receptor, rat
  • butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine
  • Mitogen-Activated Protein Kinase Kinases